Which of the following medications is subject to a REMS (Risk Evaluation and Mitigation Strategy) program?

Vyvanse (lisdexamfetamine) is a medication used to treat ADHD and binge eating disorder. It is not subject to a REMS program because it does not carry significant risks that require specific safety measures beyond standard prescribing guidelines and monitoring.

Trulicity (dulaglutide) is an injectable medication for type 2 diabetes management. While it has some potential side effects, it is not included in the REMS program because its safety profile does not require the specialized monitoring and risk communication that REMS provides.

Tivicay (dolutegravir) is an antiretroviral medication used in the treatment of HIV. Although it has specific monitoring requirements, it does not fall under the REMS program as its risks do not necessitate the same level of oversight as those medications that are subject to REMS.